EGFR and non-small cell lung carcinoma: For advanced EGFR-positive NSCLC, EGFR tyrosine kinase inhibitors (TKIs) significantly extend progression-free survival (PFS) and overall survival (OS) compared to traditional chemotherapy, while reducing the occurrence of adverse events (AEs) (3).